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Introduction: The number of subjects with tuberculosis (TB) presenting with co-occurrence of multiple chronic
medical conditions, or multimorbidity (MM) is increasing in Brazil. This manuscript aimed to characterize subjects
with TB, according to their MM status and to analyse factors associated with TB treatment outcomes.
Methods: This is a cross-sectional study that included 39,881 TB subjects reported in Brazil, in 2011. MM were
defined as any (two or more) occurrence of chronic medical conditions in a TB patient (TB–MM). Data analysis was
performed by hierarchical logistic regression models comparing TBMM with those with only TB.
Results: Of the reported TB cases in 2011, 454 (1.14%) had MM. The subjects in the age group 40–59 years
(OR: 17.89; 95% CI, 5.71-56.03) and those ≥ 60 years (OR: 44.11; 95% CI, 14.09-138.06) were more likely to develop
TB–MM. The TB–MM subjects were less likely to be male (OR: 0.63; 95% CI, 0.52-0.76), institutionalized (OR: 0.59; 95%
CI, 0.23-0.80) and live in rural areas (OR: 0.63; 95% CI, 0.42-0.95). Death from causes other than TB was higher among
TB–MM subjects (OR: 1.76; 95% CI, 1.36-2.28). Of 454 TB–MM subjects 302 (66.5%) were cured and 152 (33.5%) were
not cured. The odds of not being cured was 1.55 (95% CI, 1.04-2.32) among males, 2.85 (95% CI,
1.12-7.28) among institutionalized subjects, and 3.93 (IC 95%, 1.86-8.30) among those who were infected with HIV.
TB retreatment after previous abandonment (OR: 7.53; 95% CI, 2.58-21.97) and transfer from a treatment site
(OR: 2.76; 95% CI, 1.20-6.38) were higher for subjects not cured compared to those who were cured.
Conclusions: While TB is well recognized to be a disease engendered by social inequity, we found that even
among TB patients, those who have MM have greater inequity in terms of socioeconomic status and adverse
clinical outcomes. Addressing the problem of TB and TB–MM requires a multisectorial approach that includes
health and social service organizations.
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Worldwide, the proportion of subjects with multiple coex-
istent medical conditions, or multimorbidity (MM), is in-
creasing [1]. MM is defined as co-occurrence of multiple
diseases or medical conditions in the same individual [2].
Tuberculosis (TB) is an important chronic infectious
disease problem, which has a strong social determination
[3,4]. In 2010, it was the cause of death of 4,600 people
in Brazil and fourth most common infectious disease* Correspondence: ethel.maciel@gmail.com
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distribution, and reproduction in any mediumcause of death [5]. Because TB is a chronic infectious
disease, it frequently co-occurs with other chronic med-
ical conditions [6,7].
The prevalence of MM has often been investigated in
developed countries [8-11], but available literature on MM
in developing countries is limited. The determinants of
MM [age, sex, area deprivation (an area’s potential for
health risk from ecological concentration of poverty, un-
employment, economic disinvestment, and social disor-
ganisation [12]) and difficulty in access to health services]
have already been reported [13]. The lack of access to
health services, especially to primary care services, where
most health care is provided, may generate a wide rangetral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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layed diagnosis, disease complications, and delay in treat-
ment, which, then can affect the health of the entire
population where such individuals reside [13]. Reliable es-
timates of MM in TB subjects can prepare the health ser-
vices to better manage the health problem of their
patients living in resource-limited conditions.
This study aimed to characterize subjects with TB,
according to their MM status and to analyze factors as-
sociated with TB treatment outcomes.Patients and methods
In Brazil, TB cases are registered in the National Notifica-
tion System (SINAN) from investigation and follow-up
medical chart reviews of a TB case, and it is the principal
instrument in the country for collecting and analysing na-
tional TB data [14,15].
This is a cross-sectional study based on SINAN data-
base, including TB cases reported in Brazil in 2011.
Those subjects with missing information on TB treat-
ment outcome were excluded.
The subjects were classified as “TB and MM subjects”
(TB – MM subjects) if they had both TB and MM, and
“TB without MM subjects” (TB subjects) if they had no
MM. MM was defined as any (two or more) occurrence
of the following medical conditions in a TB patient:
arthritis, cancer, diabetes mellitus, hypertension, heart
disease, obstructive lung disease and psychiatric prob-
lems [2].
TB treatment outcomes were classified as “cured” and
“not cured”. The “not cured” group included the follow-
ing SINAN categories: abandonment, death from TB,
death from other cause than TB and development of
multidrug resistant TB (MDR TB).
The socio-demographic covariates evaluated were: age
(< 20 years, 20 – 39 years, 40 – 59 years and ≥ 60 years),
gender (female, male), skin color (white, non-white),
schooling (< 4 years, 4 to 8 years, > 8 years), area of resi-
dence (urban, rural) and institutionalization status [no,
yes (prison, shelter, orphanage, psychiatric hospital)].
The covariates related to TB features included type of
treatment (new TB case, relapse, return after abandon-
ment, transferred and unknown) and TB presentation (pul-
monary, extra pulmonary, pulmonary + extra pulmonary),
tuberculin skin test (negative, positive if higher than 10+
mm), existence of chest X-ray suspicious for TB, result of
initial bacilloscopy test, result of initial culture examination
and result of initial histopathologic examination.
Supervision status under directly observed therapy
(DOT) and the occupational setting of TB transmission
(TB acquired at workplace mainly determined by inad-
equate environments or conditions of work) were in-
cluded as covariates also.Data analysis
Initially, we compared TB – MM subjects with TB subjects
according to socio-demographic features, health-related
history and TB clinical features. Then the treatment out-
come of TB – MM subjects was evaluated according to
socio-demographic features, health-related history and TB
clinical features. Pearson chi-square test or likelihood-ratio
chi-square test, when more than twenty percent of categor-
ies had less than five observations, were used to compare
proportions. Covariates associated (p ≤ 0.10) with the out-
come of interest were included in a hierarchical logistic re-
gression model.
The covariates were grouped into a hierarchy of categor-
ies, ranging from distal determinants to proximate ones
[16]. The level 1 included socioeconomic characteristics;
level 2 variables evaluated the environmental characteris-
tics; level 3 variables were related to health conditions as-
sociated; level 4 variables assessed TB clinical features;
and level 5 variables were TB outcome/care.
As the purpose was to identify a parsimonious model to
explain the data, in each set the confounders were selected
through backward elimination, according to an alpha level
of 0.10 (p ≤ 0.10). Thus, the covariates were evaluated after
adjustment for confounders in the same set or in hierarch-
ically superior sets. This approach allows researchers to
quantify the contribution of each level of adjustment to
understand the model building strategy as well as to inter-
pret the independent associations [16].
All analyses were conducted with the StataW statistical
package, Version 9 (Stata Corp, College Station, TX, 2001).
The Institutional Review Board of the Federal Univer-
sity of Espirito Santo, Brazil, under number 121/06, ap-
proved this project.
Results
In 2011, 454 (1.14%; 95% CI, 1.04 – 1.25%) patients
among 39,881 treated cases of TB had MM as reported
by SINAN.
The study was conducted in two stages. In the first
stage, we analyzed 39,881 subjects comparing TB sub-
jects with and without MM; in the second stage, we ana-
lyzed TB treatment outcome of TB subjects with MM.
Among the 454 subjects with TB-MM, 383 had dia-
betes mellitus; 283 had hypertension; 129 had psychiatric
disease; 54 had cardiovascular disease; 32 had cancer; 32
had chronic pulmonary obstructive disease; and 9 were
reported to have arthritis. Accordingly, 93% of subjects
had two, 6% had three, and 1% had four comorbidities.
Gender distribution was different between the groups;
the prevalence of TB – MM was 1.0% among males and
1.5% among females (p < 0.001), and the proportion of
subjects with TB – MM increased with age (< 20 years:
0.1%; 20 – 39 years: 0.3%; 40 – 59 years: 1.5% and ≥
60 years: 3.6%; p < 0.001). Low school level (up to eight
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(p = 0.001). Subjects identified as whites were more preva-
lent among the TB – MM group (1.3%, p = 0.044) (Table 1).
Table 2 shows that there was no statistically significant
difference between groups according to treatment type
(p = 0.244) and TB form (p = 0.073).On the other hand,
the proportion of those with positive tuberculin skin test
was higher among those who did not have MM (99.3% TB
vs 0.7% TB – MM p= 0.003).
The proportion of histopathological examination sug-
gestive of TB was 98.1% for the subjects with TB and
1.9% for those with TB – MM (p = 0.084).
There were no differences with respect to DOTS
program coverage (p = 0.348 DOTS indication and
p = 0.347 DOTS realization) and occupational TB pro-
portion (p = 0.831).
The hierarchical multivariable model (Table 3) shows
that in the first level those subjects in the age group 40 –
59 years and those ≥ 60 years were more likely to develop
TB – MM (OR = 17.89, 95% CI 5.71 – 56.03 and OR =
44.11, 95% CI 14.09 – 138.07, respectively). The odds of
having TB – MM was lower among males (OR = 0.63,
95% CI 0.52 – 0.76).
In the second level the odds of TB – MM was lower
among subjects institutionalized (OR = 0.59, 95% CITable 1 Distribution of socio-demographic and health history
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MM multimorbidity, HIV Human immunodeficiency virus, TB Tuberculosis.
*Pearson chi-square test.0.23 – 0.80). Death from causes other than TB was
higher for subjects who had MM (OR = 1.76, 95% CI
1.36 – 2.28) (Table 3).
Concerning TB treatment outcome, 302 (66.5%) of
454 TB subjects with MM were classified as having been
cured and 152 (33.5%) as not cured (abandonment,
death from TB, death from other cause than TB and de-
velopment of MDR TB).
The proportion of subjects who were considered as
not cured was higher among males (females: 27.9%;
males: 37.5%; p = 0.032), oldest age group (< 20 years:
33.3%; 20 – 39 years: 31.5%; 40 – 59 years: 26.6%; and ≥
60 years: 40.5%; p = 0.032). Treatment outcome was not
related to schooling (p = 0.217) and skin color (p = 0.065).
Subjects who were not cured were more likely to be
infected with HIV (41.1% among cured and 58.9% among
not cured, p < 0.001) (Table 4).
Table 5 describes the subjects with MM according to
characteristics of TB presentation and TB treatment out-
come status. Return for TB treatment after abandon-
ment was higher among those who were not cured
(28.6% cured vs 71.4% not cured, p < 0.001). The propor-
tion of subjects who had a positive initial bacilloscopy
test result, positive culture, x-ray suspicious of TB and
TB presentation were similar between the two groups.characteristics of tuberculosis cases according to
TB (%) TB – MM (%) p value*
12,645 (98.5) 190 (1.5)
<0.001
26,779 (99.0) 264 (1.0)
3,296 (99.9) 3 (0.1)
<0.001
17,780 (99.7) 54 (0.3)
12,898 (98.5) 192 (1.5)
5,438(96.4) 205 (3.6)
13,953 (98.7) 182 (1.3)
0.044
22,174 (98.9) 2370 (1.1)
1,936 (98.3) 33 (1.7)
0.001
7,402 (98.5) 107 (1.5)
6,825 (99.0) 67 (1.0)
6,279 (99.1) 55 (0.9)
24,804 (98.8) 293 (1.2)
0.087
3,124 (99.2) 26 (0.8)
33.691 (98.7) 425 (1.3)
<0.001
3,938 (99.5) 19 (0.5)
29,553 (98.8) 349 (1.2)
0.331
6,238 (98.7) 83 (1.3)
21,370 (98.8) 259 (1.2)
0.005
4,672 (99.3) 34 (0.7)
Table 2 Distribution of clinical characteristics of tuberculosis cases according to multimorbidity status in Brazil, 2011
Characteristics TB TB – MM p value*
n (%) n (%)
Type of treatment (39,879)
New case 32,478 (98.9) 373 (1.1)
0.244
Relapse 2,232 (98.5) 33 (1.5)
Return after abandonment 2,514 (99.2) 21 (0.8)
Unknown 84 (100) 0 (0)
Transferred 2,117 (98.7) 27 (1.3)
TB form (39, 865)
Pulmonary 33,213 (98.9) 372 (1.1)
0.073Extrapulmonary 4,970 (98.6) 72 (1.4)
Pulmonary + extrapulmonary 1,228 (99.2) 10 (0.8)
Tuberculin skin test (6,532)
Negative 1,868 (98.6) 27 (1.4)
0.003
Positive 4,606 (99.3) 31 (0.7)
X-ray suspicious (33,297)
No 2,220 (98.6) 32 (1.4)
0.218
Yes 30,693 (98.9) 352 (1.1)
Initialbacilloscopy (32,804)
Negative 8,721 (98.9) 101 (1,1)
0.964
Positive 23,706 (98.8) 276 (1.2)
Culture (9,667)
Negative 3,389 (99.1) 31 (0.9)
0.207
Positive 6,173 (98.8) 74 (1.2)
Histopathologic examination (4,298)
Not suggestive 260 (98.9) 3 (1.1)
0.084AFB positive 1,787 (98.9) 19 (1.1)
Suggestive of TB 2,187 (98.1) 42 (1.9)
DOTS indication (37,432)
No 15,522 (98.8) 187 (1.2)
0.348
Yes 21,487 (98.9) 236 (1.1)
Under DOTS (33,504)
No 14,838 (98.8) 178 (1.2)
0.347
Yes 18,289 (98.9) 199 (1.1)
Occupational disease (24,077)
No 23,177 (98.9) 281 (1,1)
0.831
Yes 611 (98.7) 8 (1.3)
Treatment outcome (39,879)
Cured 28,625 (98.9) 302 (1.1)
<0.001
Abandonment 5,490 (99.5) 29 (0.5)
Death from TB 2,243 (98.1) 44 (1.9)
Death from other cause 2,828 (97.4) 76 (2.6)
MDR TB 239 (98.8) 3 (1.2)
AFB Acid fast bacilli, DOTS Directly observed treatment short, MDR TB Multidrug resistant tuberculosis, MM Multimorbidity, TB Tuberculosis.
*Pearson chi-square test.
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patients (77% of sample).
The proportion of subjects under the DOTS program
was lower among those considered as not cured (75.4%
cured vs 24.6% not cured, p = 0.009). There were no sta-
tistically significant differences in occupational TB ex-
posure (p = 0.698).
The hierarchical multivariate model is shown in Table 6.
It shows that males were more likely to be considered as
not cured at the end of TB treatment (OR = 1.55, 95% CI
1.04 – 2.32). In the second level, the odds of being not
cured was higher (OR = 2.85, 95% CI 1.12 – 7.28) in those
who were institutionalized. The odds of being not curedwas higher among HIV positive subjects (OR = 3.93, 95%
CI 1.86 – 8.30). Finally, in the fourth level of hierarchical
logistic model, return to TB treatment after previous aban-
donment and transfer of treatment site were higher for
subjects who were not cured compared to those who were
(OR = 7.53, 95% CI 2.58 – 21.97 and OR = 2.76, 95% CI
1.20 – 6.38, respectively).
Discussion
Prevalence of MM has wide variations across studies
reported worldwide ranging from about 1% – 70% in
general population. These variations are generally related
to methods of MM classification [11]. The proportion of
Table 3 Hierarchical multivariable analysis of the
association of multimorbidity status and characteristics
of subjects with tuberculosis in Brazil, 2011
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Pulmonary + extrapulmonary 0.72 (0.38-1.36)
Histopathologic
examination
Not suggestive of TB 1.00
AFB positive 0.96 (0.28-3.28)





Death from TB 1.18 (0.86-1.64)
Death from other cause 1.76 (1.36-2.28)
MDR TB 1.33 (0.42-4.21)
AFB Acid fast bacilli, MDR TB Multidrug Resistant Tuberculosis, MM
Multimorbidity, HIV Human immunodeficiency virus, TB Tuberculosis.
*Covariates with p < 0.10followed to next level of hierarchical model.
Table 4 Distribution of socio-demographic and health
history characteristics of cases of tuberculosis with
multimorbidity according to TB treatment outcome
status in Brazil, 2011
Characteristics Cured Notcured p
valuen (%) n (%)
Gender (454)
Female 137 (72.1) 53 (27.9)
0.032*
Male 165 (62.5) 99 (37.5)
Age (454)
<20 years 2 (66.7) 1 (33.3)
0.032**
20 –39 years 37 (68.5) 17 (31.5)
40-59 years 141 (73.4) 51 (26.6)
> 60 years 122 (59.5) 83 (40.5)
Skin color (419)
White 111 (60.9) 71 (39.1)
0.065*
Non-white 165 (69.6) 72 (30.4)
School level (267)
Illiterate 19 (57.6) 14 (42.4)
0.217*
1 – 4 years 71 (66.4) 36 (33.6)
5 – 8 years 48 (71.6) 19 (28.4)
> 8 years 42 (76.4) 13 (23.6)
Not applicable 2 (40.0) 3 (60.0)
Area of
residence (319)
Urban 195 (66.5) 98 (33.5)
0.280*
Rural 20 (76.9) 6 (23.1)
Institutionalization
(444)
No 290 (68,2) 135 (31.8)
0.018*
Yes 8 (42.1) 11 (57.9)
HIV (293)
Negative 192 (74.1) 67 (25.9)
<0.001*
Positive 14 (41.1) 20 (58.9)
Alcoholism (432)
No 238 (68.2) 111 (31.8)
0.583*
Yes 54 (65.1) 29 (34.9)
MM Multimorbidity, HIV Human immunodeficiency virus, TB Tuberculosis.
*Pearson chi-square test.
**Likelihood-ratio chi-square test.
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TB found in this study is considered low, if compared
with broad criteria of MM classification use in this study
(≥ 2 morbidities). However, we emphasize here that
there are no other estimates of MM proportion in a
similar TB population.In our study, subjects with MM tended to be older, fe-
male and have higher mortality. They were also less likely
to live in rural areas, and have been institutionalized
(prison, shelter, orphanage and others). Among TB – MM
subjects, those who were not cured were more likely to be
male, to be institutionalized, to have HIV infection; and to
start TB treatment after previous abandonment and trans-
fer of treatment site. They were also less likely to be under
DOTS.
The sample size, the utilization of data based on an in-
formation system whose quality was confirmed in previ-
ous studies, and the absence of studies with a similar
population are the main strengths of the present study.
However, some limitations should be mentioned. MM
prevalence may have been underestimated because the
information on MM was based on an optional entry in
the database. We also performed a dichotomous classifi-
cation of MM (no/yes) without considerations about se-
verity of diseases. Furthermore, there were missing
information that were not negligible. Nevertheless, our
Table 5 Distribution of clinical characteristics of cases of tuberculosis with multimorbidity according to TB treatment
outcome status in Brazil, 2011
Characteristics Cured Not cured p value
n (%) n (%)
Type of treatment (454)
New case 265 (71.1) 108 (28.9)
<0.001*
Relapse 18 (54.5) 15 (45.5)
Return after abandonment 6 (28.6) 15 (71.4)
Transferred 13 (48.1) 14 (51.9)
TB form (454)
Pulmonary 250(67.2) 122 (32.8)
0.508*Extrapulmonary 47 (65.3) 25 (34.7)
Pulmonary + extrapulmonary 5 (50.0) 5 (50.0)
Tuberculin skin test (58)
Negative 15 (55.5) 12 (44.5) <0.001**
Positive 30 (96.8) 1 (3.2)
X-ray suspicious of TB (384)
No 17 (53.1) 15 (46.9)
0.136*
Yes 234 (66.5) 118 (33.5)
Initial bacilloscopy (377)
Negative 63 (62.4) 38 (37.6)
0.295*
Positive 188 (68..1) 88 (31.9)
Culture (105)
Negative 17 (54.8) 14 (45.2)
0.271*
Positive 49 (66.2) 25 (33.8)
Histopathologic examination (64)
Not suggestive of TB 0 (0) 3 (100)
0.015**AFB positive 8 (42.1) 11 (57.9)
Suggestive of TB 28 (66.7) 14 (33.3)
Under DOTS (377)
No 112 (62.9) 66 (37.1)
0.009*
Yes 150 (75.4) 49 (24.6)
Occupational disease (289)
No 193 (68.7) 88 (31.3)
0.698**
Yes 6 (75.0) 2 (25.0)
AFB Acid fast bacilli, DOTS Directly observed treatment short, MM Multimorbidity, TB Tuberculosis.
*Pearson chi-square test.
**Likelihood-ratio chi-square test.
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power. Although we recognize that there is no statis-
tical gain, we chose to work with all subjects without
MM as comparison group since the database was struc-
tured and would not have involved additional direct
assessments.
The conceptual model of simultaneous occurrence of
multiple diseases in the same subject includes, among
their causes, the age of populations, genetics and bio-
logical risk factors, life style, social environment, physical
environment and health care support [17]. The conse-
quences of MM include increase in mortality, impaired
functional status, decreased of quality of life, complica-
tions of treatment and higher utilization of health care
system [17]. In this study we compared one of those
consequences – TB occurrence due to impaired func-
tional status, with some causes and others consequences
as described below.
The association between MM and age is strong and
well recognized [11,18]. MM prevalence in elderlypeople may reach 71.8% [11]. Furthermore TB control in
the elderly remains a challenge because of the limita-
tions of the existing tools for the diagnosis and treat-
ment of MM [7]. These data agree with our findings in
which subjects ≥ 60 years had 44 times more chances of
have TB and MM.
Gender type is associated with both TB [6] and MM
[11]. It is postulated that men develop TB more often
[6], but MM is more frequent in women [18]. We
showed that simultaneous occurrence of TB and MM
was lower for males [6,19].
Subjects identified as white were more prevalent
among TB subjects with MM. This finding disagrees
with a study performed in United States where non-
whites were more than seven times more likely than
whites to acquire TB in general population; the age-
adjusted risk of TB was especially high among Asians
[20]. In Brazil, the diagnosis of disease other than TB
may be more common in those with greater access to
health care services.
Table 6 Hierarchical multivariate analysis of the
association of TB treatment outcome status and
characteristics of subjects with tuberculosis and
multimorbidity in Brazil, 2011
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Type of TB treatment
New case 1.00
Relapse 1.81 (0.82-4.01)





DOTS Directly observed treatment short, MM Multimorbidity, HIV Human
immunodeficiency virus, TB Tuberculosis.
*Covariates with p < 0.01 followed to next level of hierarchical model.
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was higher among those in the TB-only group, com-
pared to the TB – MM group. Level of education is re-
lated to a socioeconomic condition of an individual,
which can affect the probability of having TB [21] and
MM [12,13].
No differences in treatment type and TB form or tuber-
culin skin test were found between the groups, although
these factors are important in the disease diagnostic
process [22].
The higher mortality from causes other than TB
among subjects who had MM was expected. MM is as-
sociated with high mortality, reduced functional status,
and increased use of both inpatient and ambulatory
health care [23]. Subjects with MM may be prone to
treatment failure and TB-drug intolerance and there-
fore, need a longer duration of treatment. However at
the end of the ninth month of TB treatment (time of
standard treatment) only one (0.2%) and twelve (2.6%)
of the subjects with TB and TB-MM.Concerning the treatment outcome, the proportion of
subjects with MM who were considered as cured was
below the recommended target of least 85% by the
WHO [24].
The proportion of subjects who were considered as not
cured was higher for males and older subjects. Male gen-
der is associated with appearance of the disease and poor
outcomes in TB patients [25]. As expected, older groups
were found to have more advanced disease at the time of
diagnosis, and a higher proportion had comorbidities.
They also had significantly higher mortality compared
with the younger age groups [26].
The institutionalized subject deserves attention in moni-
toring the evolution of TB, since this factor may act as an
impediment in the treatment of the disease [27]. In this
study, such issue was more evident in other institutions
than prisons and psychiatric hospitals. It was most com-
mon in subjects institutionalized in rehabilitation clinics
where the alcohol and other drugs abuse may affect treat-
ment adherence and slows or prevent disease cure [28,29].
This reinforces the importance of partnership between the
TB Control program and Mental Health program with the
aim of incorporating intervention measures to align TB
and addiction treatment [28].
Subjects with HIV infection were less likely to achieve
TB cure, most likely due to impaired immunity [30] and
the possible interaction between medications used in the
treatment of AIDS and TB [31]. With respect to subjects
who did not undergo HIV testing and were not cured, it
is assumed that the fact of not having known their im-
munological status may hide the existence of immuno-
suppression. Similar findings have also been reported in
other studies [29,32].
Those subjects who resumed treatment had a lower
chance of achieving TB cure and subjects who undergo
treatment during transfer also contribute to adverse treat-
ment outcome in this study and agree with fidings among
HIV subjects [33]. Nevertheless these associations were
not found among Brazilian diabetics subjects [34].
Conclusions
Tuberculosis remains a disease of disparity. Socio-
economic determinants such as poverty, food insecurity,
malnutrition and overcrowding besides being risk factors
for TB infection, are also related to poor TB treatment
outcome [3]. MM also increases this iniquity contribut-
ing to unfavourable clinical outcomes and treatment re-
sponse in patients with TB.
In Brazil the recent-implemented policy to supplement
income for vulnerable patients called “Brazil without
poverty” is expect to reach 16 million people in the next
five years [35]. With this program we expect to see an
impact resulting in decline in TB and TB – MM preva-
lence among the poor and disadvantaged.
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